Olymvax Biopharmaceuticals 欧林生物
11 significant filings since 29 May 2026: 2 on share pledge, 1 on rumour clarification and 2 on pledge released, and 4 other kinds. The latest, on 1 Sep 2026: 成都欧林生物科技股份有限公司董事兼高级管理人员减持股份计划公告. 2 unverified reports logged, the latest on 17 Jul 2026.
自 29 May 2026 起有 11 份重大公告：share pledge 2 份、rumour clarification 1 份、pledge released 2 份，另有 4 类。最新一份（1 Sep 2026）：成都欧林生物科技股份有限公司董事兼高级管理人员减持股份计划公告。记录了 2 条未经核实的报道，最新一条见于 17 Jul 2026。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 19 Aug 2022 | 华安证券 | 谭国超,任雯萱 | Buy 买入 | ▼ | Outperform 增持 |
| 9 May 2022 | 华安证券 | 谭国超,任雯萱 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 山西证券 | 邓周宇,魏赟,陈进 | Outperform 增持 | 14 May 2026 | 1 | — |
| 华安证券 | 谭国超,李雨涵 | Outperform 增持 | 21 Nov 2025 | 1 | — |
| 西南证券 | 杜向阳 | Unrated | 1 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。